These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1936 related articles for article (PubMed ID: 28632866)

  • 21. Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.
    Metcalfe K; Gershman S; Lynch HT; Ghadirian P; Tung N; Kim-Sing C; Olopade OI; Domchek S; McLennan J; Eisen A; Foulkes WD; Rosen B; Sun P; Narod SA
    Br J Cancer; 2011 Apr; 104(9):1384-92. PubMed ID: 21487411
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ovarian cancer in BRCA1/2 mutation carriers: The impact of mutation position and family history on the cancer risk.
    Teixeira N; Mourits MJ; Vos JR; Kolk DM; Jansen L; Oosterwijk JC; Bock GH
    Maturitas; 2015 Oct; 82(2):197-202. PubMed ID: 26239500
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.
    Antoniou AC; Durocher F; Smith P; Simard J; Easton DF;
    Breast Cancer Res; 2006; 8(1):R3. PubMed ID: 16417652
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer.
    Loman N; Johannsson O; Kristoffersson U; Olsson H; Borg A
    J Natl Cancer Inst; 2001 Aug; 93(16):1215-23. PubMed ID: 11504767
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
    Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
    J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Familial clustering of site-specific cancer risks associated with BRCA1 and BRCA2 mutations in the Ashkenazi Jewish population.
    Simchoni S; Friedman E; Kaufman B; Gershoni-Baruch R; Orr-Urtreger A; Kedar-Barnes I; Shiri-Sverdlov R; Dagan E; Tsabari S; Shohat M; Catane R; King MC; Lahad A; Levy-Lahad E
    Proc Natl Acad Sci U S A; 2006 Mar; 103(10):3770-4. PubMed ID: 16537453
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cancer risks for Australian women with a BRCA1 or a BRCA2 mutation.
    Suthers GK
    ANZ J Surg; 2007 May; 77(5):314-9. PubMed ID: 17497966
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of BRCA1 and BRCA2 mutations in a large United States sample.
    Chen S; Iversen ES; Friebel T; Finkelstein D; Weber BL; Eisen A; Peterson LE; Schildkraut JM; Isaacs C; Peshkin BN; Corio C; Leondaridis L; Tomlinson G; Dutson D; Kerber R; Amos CI; Strong LC; Berry DA; Euhus DM; Parmigiani G
    J Clin Oncol; 2006 Feb; 24(6):863-71. PubMed ID: 16484695
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
    Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
    Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry.
    Nanda R; Schumm LP; Cummings S; Fackenthal JD; Sveen L; Ademuyiwa F; Cobleigh M; Esserman L; Lindor NM; Neuhausen SL; Olopade OI
    JAMA; 2005 Oct; 294(15):1925-33. PubMed ID: 16234499
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Breast and ovarian cancer risks in a large series of clinically ascertained families with a high proportion of BRCA1 and BRCA2 Dutch founder mutations.
    Brohet RM; Velthuizen ME; Hogervorst FB; Meijers-Heijboer HE; Seynaeve C; Collée MJ; Verhoef S; Ausems MG; Hoogerbrugge N; van Asperen CJ; Gómez García E; Menko F; Oosterwijk JC; Devilee P; van't Veer LJ; van Leeuwen FE; Easton DF; Rookus MA; Antoniou AC;
    J Med Genet; 2014 Feb; 51(2):98-107. PubMed ID: 24285858
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an International Prospective Breast Cancer Family Registry population-based cohort study.
    Goodwin PJ; Phillips KA; West DW; Ennis M; Hopper JL; John EM; O'Malley FP; Milne RL; Andrulis IL; Friedlander ML; Southey MC; Apicella C; Giles GG; Longacre TA
    J Clin Oncol; 2012 Jan; 30(1):19-26. PubMed ID: 22147742
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of Age at Primary Breast Cancer on Contralateral Breast Cancer Risk in BRCA1/2 Mutation Carriers.
    van den Broek AJ; van 't Veer LJ; Hooning MJ; Cornelissen S; Broeks A; Rutgers EJ; Smit VT; Cornelisse CJ; van Beek M; Janssen-Heijnen ML; Seynaeve C; Westenend PJ; Jobsen JJ; Siesling S; Tollenaar RA; van Leeuwen FE; Schmidt MK
    J Clin Oncol; 2016 Feb; 34(5):409-18. PubMed ID: 26700119
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prospective study of breast cancer risk for mutation negative women from BRCA1 or BRCA2 mutation positive families.
    Harvey SL; Milne RL; McLachlan SA; Friedlander ML; Birch KE; Weideman P; ; Goldgar D; Hopper JL; Phillips KA
    Breast Cancer Res Treat; 2011 Dec; 130(3):1057-61. PubMed ID: 21850394
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Family history of cancer and cancer risks in women with BRCA1 or BRCA2 mutations.
    Metcalfe K; Lubinski J; Lynch HT; Ghadirian P; Foulkes WD; Kim-Sing C; Neuhausen S; Tung N; Rosen B; Gronwald J; Ainsworth P; Sweet K; Eisen A; Sun P; Narod SA;
    J Natl Cancer Inst; 2010 Dec; 102(24):1874-8. PubMed ID: 21098759
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Breast cancer risk in BRCA1/2 mutation carriers and noncarriers under prospective intensified surveillance.
    Engel C; Fischer C; Zachariae S; Bucksch K; Rhiem K; Giesecke J; Herold N; Wappenschmidt B; Hübbel V; Maringa M; Reichstein-Gnielinski S; Hahnen E; Bartram CR; Dikow N; Schott S; Speiser D; Horn D; Fallenberg EM; Kiechle M; Quante AS; Vesper AS; Fehm T; Mundhenke C; Arnold N; Leinert E; Just W; Siebers-Renelt U; Weigel S; Gehrig A; Wöckel A; Schlegelberger B; Pertschy S; Kast K; Wimberger P; Briest S; Loeffler M; Bick U; Schmutzler RK;
    Int J Cancer; 2020 Feb; 146(4):999-1009. PubMed ID: 31081934
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers.
    Ding YC; McGuffog L; Healey S; Friedman E; Laitman Y; Paluch-Shimon S; Kaufman B; ; Liljegren A; Lindblom A; Olsson H; Kristoffersson U; Stenmark-Askmalm M; Melin B; Domchek SM; Nathanson KL; Rebbeck TR; Jakubowska A; Lubinski J; Jaworska K; Durda K; Gronwald J; Huzarski T; Cybulski C; Byrski T; Osorio A; Cajal TR; Stavropoulou AV; Benítez J; Hamann U; ; Rookus M; Aalfs CM; de Lange JL; Meijers-Heijboer HE; Oosterwijk JC; van Asperen CJ; Gómez García EB; Hoogerbrugge N; Jager A; van der Luijt RB; ; Easton DF; Peock S; Frost D; Ellis SD; Platte R; Fineberg E; Evans DG; Lalloo F; Izatt L; Eeles R; Adlard J; Davidson R; Eccles D; Cole T; Cook J; Brewer C; Tischkowitz M; Godwin AK; Pathak H; ; Stoppa-Lyonnet D; Sinilnikova OM; Mazoyer S; Barjhoux L; Léoné M; Gauthier-Villars M; Caux-Moncoutier V; de Pauw A; Hardouin A; Berthet P; Dreyfus H; Ferrer SF; Collonge-Rame MA; Sokolowska J; Buys S; Daly M; Miron A; Terry MB; Chung W; John EM; Southey M; Goldgar D; Singer CF; Tea MK; Gschwantler-Kaulich D; Fink-Retter A; Hansen TV; Ejlertsen B; Johannsson OT; Offit K; Sarrel K; Gaudet MM; Vijai J; Robson M; Piedmonte MR; Andrews L; Cohn D; DeMars LR; DiSilvestro P; Rodriguez G; Toland AE; Montagna M; Agata S; Imyanitov E; Isaacs C; Janavicius R; Lazaro C; Blanco I; Ramus SJ; Sucheston L; Karlan BY; Gross J; Ganz PA; Beattie MS; Schmutzler RK; Wappenschmidt B; Meindl A; Arnold N; Niederacher D; Preisler-Adams S; Gadzicki D; Varon-Mateeva R; Deissler H; Gehrig A; Sutter C; Kast K; Nevanlinna H; Aittomäki K; Simard J; ; Spurdle AB; Beesley J; Chen X; Tomlinson GE; Weitzel J; Garber JE; Olopade OI; Rubinstein WS; Tung N; Blum JL; Narod SA; Brummel S; Gillen DL; Lindor N; Fredericksen Z; Pankratz VS; Couch FJ; Radice P; Peterlongo P; Greene MH; Loud JT; Mai PL; Andrulis IL; Glendon G; Ozcelik H; ; Gerdes AM; Thomassen M; Jensen UB; Skytte AB; Caligo MA; Lee A; Chenevix-Trench G; Antoniou AC; Neuhausen SL;
    Cancer Epidemiol Biomarkers Prev; 2012 Aug; 21(8):1362-70. PubMed ID: 22729394
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain.
    Milne RL; Osorio A; Cajal TR; Vega A; Llort G; de la Hoya M; Díez O; Alonso MC; Lazaro C; Blanco I; Sánchez-de-Abajo A; Caldés T; Blanco A; Graña B; Durán M; Velasco E; Chirivella I; Cardeñosa EE; Tejada MI; Beristain E; Miramar MD; Calvo MT; Martínez E; Guillén C; Salazar R; San Román C; Antoniou AC; Urioste M; Benítez J
    Clin Cancer Res; 2008 May; 14(9):2861-9. PubMed ID: 18451254
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers.
    Rebbeck TR; Kauff ND; Domchek SM
    J Natl Cancer Inst; 2009 Jan; 101(2):80-7. PubMed ID: 19141781
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study.
    Kauff ND; Domchek SM; Friebel TM; Robson ME; Lee J; Garber JE; Isaacs C; Evans DG; Lynch H; Eeles RA; Neuhausen SL; Daly MB; Matloff E; Blum JL; Sabbatini P; Barakat RR; Hudis C; Norton L; Offit K; Rebbeck TR
    J Clin Oncol; 2008 Mar; 26(8):1331-7. PubMed ID: 18268356
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 97.